Shattuck Labs provided a corporate update and highlighted upcoming key milestones anticipated in 2023. Clinical Milestones Expected in 2023: ARC Platform – SL-172154: Complete data from Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer expected midyear 2023; Initial data from Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected midyear 2023; Initial dose-escalation data, as monotherapy and in combination with azacitidine, for Phase 1A/B clinical trial of SL-172154 in AML and HR-MDS expected in 1H’2023 ; Complete dose-escalation data, as monotherapy and in combination with azacitidine, for Phase 1A/B clinical trial of SL-172154 in AML and HR-MDS and initial dose-expansion cohort data expected in 2H’2023; Initial data from Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer expected 2H’2023. SL-279252: Go/no-go decision from the Phase 1 dose-escalation clinical trial of SL-279252 in advanced solid tumors or lymphoma in 1Q’2023 GADLEN Platform – GADLEN Preclinical Product Candidates: Additional clinical development detail and further program guidance regarding the advancement of potential product candidates from the GADLEN platform in 2023
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Questions or Comments about the article? Write to editor@tipranks.com